Method of producing alcaloids of ergot

专利摘要:
Ergot alkaloids having interesting pharmacological activities, for instance in the therapy of migraine or hypertension. Such compounds are obtained in a fermentative process using mutant strains of Claviceps purpurea eventually hydrogenating the products thus obtained.
公开号:SU735154A3
申请号:SU782606999
申请日:1978-04-18
公开日:1980-05-15
发明作者:Бикко Энцо；Луиза Бьянчи Мария；Мингетти Анаклето；Спалла Челестино
申请人:Сочиета Фармасьютичи Италиа С.П.А. (Фирма)；
IPC主号:

专利说明:

(54) METHOD FOR OBTAINING ALKALOID ALUMNOIDES: -. one . V. ..... ,, ,,:,. FIELD OF THE INVENTION The invention relates to chemical processing and the production of ergot alkaloids. The proposed alkasoids are new and the way they are obtained in the patent and scientific technical literature is not described. The purpose of the invention, the shadow is to obtain ergot alkaloids of the general form Bi on) - NH where Rj (-methyl, ethyl, isopropyl, ..., p, "Ng- | 1 -Cn 0-1.: -..- -..,.;. ::. Unsubstituted C-C-alkyl group, halogen-substituted linear Co, -Sb-alkyl group, halogen substituted butyl group, , Ra - С-С-alkyl, С-С / -alkoxy, halogen and 9,10-dihydropro-derivatives. This goal is achieved by the fact that the strain Ctaviceps purpurea АТСС 153ВЗ, CIZ.aviceps purpurea АТСС 20103 or cCaviceps purpurea: АТСС 20019, dependent, from non-hydroxylated amino acids, are grown on a nutrient medium containing non-hydroxylated amino acid as a precursor, followed by separation of the target product. In addition to togr, leucine, phenylalanium; V-pyrazolyl-, furyl-, pyridylalanine; linear С С7 -.- amino acids or halogen-substituted natural amino acids. New ergot alkaloids exhibit pharmacology properties (see data in Table 1). Pharmacological properties depend on the type of radicals R, and R y.f and the activity of these alkalo-.
The yields can vary depending on whether the double bond is present at position 9-10 or is removed by hydrogenation.
For example, new ergot alkaloids of general formula I, in which RI is CU and Rg is unsubstituted benzyl, possess vasoconstrictor activity
and therefore they can be used in Migraine: Derivatives in which R is isopropyl, and R is a substituted benzyl or aliphatic chain having a hydrogenated double bazine, 9-10, have adrenolytic activity and affect the central nervous system, they can be used dp treatment of hypertension.
Table 1
Ergotamine
5 -Dibenzyl-5 -n-chlorobenzyl ergotamine.
Dihydroergotamine
5 -Dibenzyl-5-p-chlorobenzyldihydroergotamine
Dihydroergristine
5-Dibenzyl-5-p-chlorobenzyldihydroergocristine
. All three new derivatives exhibit increased β-adrenolytic activity compared with their related compounds, both when used in vitro and in vivo. On the other hand, acute toxicity decreases to some extent. The proposed ergot alkaloids are lysergic acid amides containing a cyclone peptide fragment, obtained biosynthetically as a result of the condensation of 3-amino acids, one of which, i.e., proline, is present in all substances. The cyclo moiety consists, respectively, in the case of ergotamine (, R, CH,) from one phenylalanine molecule and one β-hydroxyalanine molecule; in the case of ergocristine (R CE (CHo,) j a.) from one phenylalanine molecule and one hydroxy-Raline molecule; in the case of ergocryptin {Ri, “CHCCHo Ja Ka CHaCH (CH3) a) - ns leucine molecule and one molecule of C-hydroxyvylin.
Strains of C. purpurea, pre-treated with a mutagenic agent and. those who lack the ability to grow in the absence of non-hydroxylated amino acids (i.e. phenylalanine or leucine) acquire the ability to form alkaloids that contain, as a final amino acid, an analogue present in the medium when growing in the presence of an amino acid, to the action of which they were mutagenically dependent Or its analogues.
It becomes possible to obtain significantly higher yields of an alkaloid containing an analogue of an amino acid by adding small amounts of the amino acid required by the strain. At the first stage of fermentation, called .Trofofazoy ,. and the subsequent addition of significant amounts of the analogue in the second stage of fermentation, called idiophase.
Ergot alkaloids are prepared as follows ..
The squamous mockling film from the strains of the producers of ergotamine or ergocristine or ergocryptin is suspended in sterile water and crushed by shaking in a blender, then filtered through a silk fabric: The filtrate, containing mostly single-cell fragments, is irradiated with UV light to achieve 9- V9% mortality. The suspension is diluted with sterile water and placed in a Petri dish on a solid medium, which is additionally added with an amino acid, to find which mutants are required (i.e., leucine or phenylalanine) .. After incubation for the required time, the expanded colonies are transferred according to the well-known method on Wednesday, free of amino acids, for which the required mutants are sought. Strains capable of growing in the first medium and not capable of growing in the second medium are dependent on the amino acid. They are stored by successive transfers to the medium containing the amino acid. To produce alkaloids, the desired mutants are grown in a liquid medium containing a carbon source, a nitrogen source, a phosphorus source, a sulfur source and several mineral salts, as well as an amino acid that is required by the strain. The amount of amino acid can vary within 0.5-2 g / l. After incubation for 3-5 days, the amino acid, the desired strain, is added to the culture in an amount of 3-6 g / l and then incubated for an additional 9-1i days. so that the total incubation time was 14 days. Cultivation (fermentation) can be carried out in shake flasks or in fermentors of various sizes. . . By the end of the fermentation, the broth of the culture contains an analogue of an alkaloid and small amounts of the usual alkaloid. The alkaloid analog is extracted as follows. The broth is filtered and the mycelium is extracted several times with 4% aqueous solution of tartaric acid. After filtration, the aqueous phase is alkalinized, to pH. 9 Sodium hydroxide and extracted with gaseous methylene. The organic phase is concentrated, precipitated and recrystallized as a phosphoric acid salt. A free base is obtained from phosphorus, and ej7O is additionally enriched with natural alkaloids on silica gel column chromatography pathways. Then, the separation of new products from natural products is carried out by fractional crystallization. The concentration of alkaloids o / is determined by specrophotometrically after a subcluster; shivani reagent van urk, and the calculation is carried out at 550 nm. . The ratio between the natural and substituted amino acids present in the peptide fragment is determined by acid hydrolysis of the alcaloid and quantitative determination of monoamino acid. For Identification of end products is performed using conventional methods of physicochemical analysis (NMR, IR and UV spectroscopy, mass spectrometry, etc.). The phenylalanine-consuming mutants of ergocristine or ergotamine shchamma producers can produce alkaloids that are incorporated into the phenylalanine fragment of the phenylalanine molecule substituted on the benzene ring by halogen, alkyl or alkoxy. They can also produce alkaloids by introducing into the phenylalanine fragment its isoesters, such as thienylalanine, oL - and P) pyrazolylalanine, furylalanine, pyridyllaylin. The leucine-consuming mutants of ergocryptin prod- uct strains can produce alkaloids that are embedded in the leucine moiety of the linear molecule (α-amino acids, and 2–7 atomic atoms C. They can also produce alkaloids by introducing JB leucine fragments of natural amino acids replaced by halogen atoms, for example such as 5.5, 5-trifluoro-leucine Example 1. 5-Dibenzyl-5-h-chlorobenzyl-ergocristine Mycelial film of a 12-day bevel on solid medium Bp 3 (see attached Table 2) of ATCC 20103 strain C. purpurea ergocristine producer in submerged the culture is transferred to 50 ml of sterile distilled water and fragmented in a VarinH1 mixer for 20 seconds. The suspension is filtered through a silk cloth and 5 ml of the filtrate is kept under light (520 µW / cm) of the UV lamp for 45 seconds. The dilutions are placed on solid TM medium (see Table 2), to which 1% phenylalanine is additionally added, in Petri dishes. The plates are incubated at 28 ° C for 10-12 days. The expanded colonies are transferred by a well-known method. wa on cups using the fingerprint method on solid TM medium in Petri dishes, and these h shki incubated at 28 ° C for 10-12 days .. During sorting 3000 colonies were found, four strains that were unable to grow on minimalnm amount cFe TM gical. These strains are confirmed by isolation in the TM medium as well as in the TM medium to which phenylalanine is added and two of them are phenoyasan dependent mutants. Ten 300 ml flasks, each containing 50 ml of TG medium (see Table 2), in which 1 g / l of phenylalanine was added, are sterilized at 100 ° C for 30 minutes and each flask is inoculated with a target film corresponding to Approximately 1 cm of solid media cut off pep 3 mutant strain. These flasks are incubated at 23 ° C for 4 days in a rotary shaker at a rotation speed of 225 rpm. These flasks correspond to the vegetation phase. Fifty 300 ml flasks, each containing 30 ml of T25 medium (cTvi. Table 2), to which 1 g / l of 1-phenylalanine is added, sterilized at 25 min, inoculated with 5 ml of vegetative culture and incubated at. 23 ° C in the same rocking chair used for the vegetation phase. After 4 days, 4 g / l of p-chlorophenylalanine was added to the flasks.
After ID days of incubation, the cultures are grouped, resulting in about 2 liters of broth, which is obtained.
contains 700 g kg / MG peptide alkaloids. They are extracted as follows. once om
The culture broth is filtered, the filtrate is discarded, and the mycelium is suspended in 5% aqueous solution viny
acid. After shaking and filtering, the precipitate is extracted two more times. The combined filtrates are alkalinized to pH 9 with 2iJ% -. a solution of NaOH and Ektratragrutot several times with methylene chloride. The organic phase is washed with water, concentrated and precipitated with hexane. The raw material thus obtained (0.9 g) is decoloured with activated carbon, dissolved in 10 ml of 95% ethanol, and 0.8 ml of a t5% -Horo solution is added. The resulting 15ast1vore is heated with a reverse REFRIGERATOR in the dark for 30 minutes and kept at 3 ° C for 5 days. . .
 As a result, phosphate (0.5 g) crystallizes, which contains a mixture of ergocristine (20%) and 5-dibenzyl-5-P-chlorobenzyl-ergocristine (80%). From the phosphate platingM, an untreated base is obtained, extracted
  and twist acetone. The crystallized product is chromatographed on a silica gel column using a mixture of CHCl 2 and methanol as the eluant (initial ratio 99: 1, final ratio 90: 10). After discarding. fractions containing dextrochezois isomers, the fraction enriched in 5-dienzyl-5-L-chlorobenzylphenyl 6,6E ect6n6m is isolated. A sequential product is isolated by sequential recrystallization from benzene, methanol, acetone; (100 g). Kislbt hydrolysis peyd-; the amino acid gives the amino acids ProlH and p-chlorophenylalanine in 1: 1 taper. As a result, it is alkaline; . lysergic acid and 3,3-dimethylpyroinogride are obtained by hydrolysis
Acid. -. - ./ .. ;.
pli, me r 2. The mutant strain obtained as a result of treatment with UV light, according to example 1, is used for inoculations and flasks of the PS medium under the same conditions as described; they are glued into 1. At the end of the vegetation phase pooled, resulting in 40d ml of culture broth, which is used for. , a 10-liter fermenter inoculum containing a liter of T25 medium, to which 1% fenylalanine is added. The fermenter is supplied with a discoturbine type stirrer operating with aeration corresponding to 0.5 l / min and a rotation speed of 600 rpm. Incubation temperature. . After four
days after the start of fermentation (4% P-chlorophenylalanine is added to the culture. On the 13th day of fermentation, the crop is harvested from the culture broth.
The total content of peptide alkaoids corresponds to 600 μg / mp, 65%
which is 5-dibenzyl-5-p-chlorobenzyl ergocrystin. The extraction is carried out according to the method described in the example 1.
PRI me R 3. The same strain as in example 1, is fermented in flasks
under the same conditions as in example 1, both during the growing season and during the production stage, the only difference is that
4th day of fermentation. P-fluoro is added. fenil. On the 14th day of fermentation by extracting the broth, 750 µg / mg of peptide alkaloids are obtained, and 80% of this quantity is 5-dibenzyl-5-L-fluorobenzyl-ergocristin. . :. .
Example 4: The ATCC strain 15383, an ergotamine producer, is treated with UV light under the conditions described in Example 1. As a result of the treatment
two phenylalanine-dependent mutants are obtained for 2000 counted colonies. . -. ; . , . -. One of these strains is used as a graft material, which is added to the fermentation flask under the same conditions as tex in Example 1, as during vegetative,
and during the producing phases. On the 4th day of the production phase, 4% p-chlorophenyl alanine was added. On day 14, 9GO µg / ml of peptide alkaloids is obtained from the buloin, and 0% of this amount is 5-dibenzyl-5-P fluorobenzyl-ergotamine.
Example 5: Strain ATCC 20019, ergocryptin producer, is treated with UV light as described in Example 1. As a result of the treatment, three leucine dependent mutants from 4000 counted colonies are obtained. . ;
One of these strains is fermented under the conditions described in example 1, the only difference being that during the vegetation and production phases,
1 g / l and 2 g / l L-leucine, respectively. On day 4 of the production phase, b g / l of L-norvaline is added. By the 14th day, the bulbs contained 1000 µg / ml of peptide alkaloids, with 80% of this amount being 5-diiso-: butyl-5-c-propylene ergocriptine.
Example 6. Leucine dependent
:strain,. used in example 5, fermented in flasks under the same conditions as in the vegetation phase, and
the production phase, then 3 g / l of 5,5.5-trifluoro leucine is added, on the 4th day of the production phase ... On the 14th. The day of fermentation, the broths are combined and extracted according to the general procedure described earlier. The total yield of peptide alkaloids is 600 µg / mp with 60% incorporation of trifluoro leucine.
The proposed method allows to obtain new ergot alkaloids with pharmacological activity.
T a b l. and c a 2

权利要求:
Claims (2)
[1]
Claims 1. Method for producing ergot alkaloids of the general formula
-ABOUT
"-Oh,., - en,
S
an unsubstituted linear C-C-alkyl group, a halogen-substituted linear C-C5 alkyl group, a halogen 5 substituted butyl group, R ,, -GI-C4 alkyl, Cj-C-alkoxy, halogen,
and 9,10-dihydro derivatives, characterized in that the strain
0 C aviceps purpurea ATGC 15383, C aviceps purpurea ATCC 20103 or C viceps purpurea ATCC 20019, depending on the non-hydroxylated amino acids, is grown on a nutrient medium containing non-hydroxylated agPtic acid with a precursor as a precursor with a fraction of segregated extract, followed by a segregated extract with a fraction of segregated non-hydroxylated agPTP with an extract with a separate extract, followed by a mixture of non-hydroxylated agPT acid with a proliferant and a mixture, with a mixture of non-hydroxylated agPT acid with a proliferator and an extract with a fraction of segregating extract with a mixture of non-hydroxylated agPTS with purpuraa ATCC 20038 or ATCP 15383;
0
[2]
2. A method according to claim 1, characterized in that leucine, fenilalanin is used as the non-hydroxylated amino acid; feyzinein substituted by halogen, alkyl, alkoxy radical / thienyl; |, -piraeolil-, furyl-, L1yridylayy11yn; linear C-C - amino acids or halogen-substituted natural amino acids.

类似技术:

---

公开号 | 公开日 | 专利标题

---

US5076973A|1991-12-31|Synthesis of dolastatin 3

---

SU735154A3|1980-05-15|Method of producing alcaloids of ergot

---

EP1751272A2|2007-02-14|Production of tacrolimus | using new streptomyces species

---

US3973608A|1976-08-10|Microbial production of certain isoflavones

---

US4542135A|1985-09-17|9'Thia-ergots

---

EP0703917A1|1996-04-03|Indolocarbazole compound useful as proteinkinase c inhibitor

---

US3974184A|1976-08-10|Microbial production of certain isoflavones

---

HOEHN et al.1995|3'-Demethoxy-3'-hydroxystaurosporine, a novel staurosporine analogue produced by a blocked mutant

---

EP0372986B1|1993-03-24|Compound ks-505 and a process for producing the same

---

US3224945A|1965-12-21|Process for the production of ergot alkaloids

---

JP2002518057A|2002-06-25|Mumbaistatin, its production method and its use as a medicament

---

US3264195A|1966-08-02|Process for the preparation of septacidin and derivatives

---

FR2550549A1|1985-02-15|NOVEL CLAVINE-PRODUCING STRAIN, PROCESS FOR PREPARING THE SAME, AND MICROBIOLOGICAL PROCESS FOR THE PRODUCTION OF CLAVINE ALKALOIDS

---

Wang et al.1994|31-Homorifamycin W, a novel metabolite from Amycolatopsis mediterranei

---

FI58514C|1981-02-10|SAMTIDIG FRAMSTAELLNING AV ERGOKORNIN ERGOKRYPTIN OCH ERGOMETRIN MED HOEGT UTBYTE MED TILLHJAELP AV ETT FERMENTATIVT FOERFARANDE

---

US4086141A|1978-04-25|Process for the fermentation production of ergoline derivatives

---

US3597324A|1971-08-03|Preparation of the antibiotic rifamycin sv

---

JP2578486B2|1997-02-05|New substance KS-502

---

EP0171283A2|1986-02-12|Hapalindoles

---

JP2607259B2|1997-05-07|New substances KS-504

---

SU1760986A3|1992-09-07|Method of 4ъ-deoxy-13|-dihydro-4ъ-iododoxorubicine synthesis

---

US2988490A|1961-06-13|Production of rifomycin

---

JP2779855B2|1998-07-23|Compound KS-505 and method for producing the same

---

KR820001221B1|1982-07-02|Process for preparing hydroxyamino hydrocarbon-phosphonic acid derivatives

---

JPH05255184A|1993-10-05|New compound ilicicolinic acid a or b

同族专利:

---

公开号 | 公开日

---

JPS53132599A|1978-11-18|

---

CH637658A5|1983-08-15|

---

CS212760B2|1982-03-26|

---

DK165778A|1978-10-20|

---

FR2387989B1|1980-07-04|

---

IE46797B1|1983-09-21|

---

ATA260378A|1982-06-15|

---

GB1584464A|1981-02-11|

---

DE2816773A1|1978-10-26|

---

US4230854A|1980-10-28|

---

HU175173B|1980-05-28|

---

IE780759L|1978-10-19|

---

AT369783B|1983-01-25|

---

DK145701C|1983-07-18|

---

NL7804174A|1978-10-23|

---

SE7804362L|1978-10-20|

---

DK145701B|1983-01-31|

---

CA1113410A|1981-12-01|

---

FR2387989A1|1978-11-17|

---

BE865921A|1978-07-31|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

CH508628A|1968-06-25|1971-06-15|Sandoz Ag|Process for the preparation of new heterocyclic compounds|

---

CH534683A|1970-05-26|1973-03-15|Sandoz Ag|Process for the production of new ergot peptide alkaloids|

---

DK140017C|1973-07-09|1979-11-05|Sandoz A.G.|

---

HU172649B|1975-04-24|1978-11-28|Gyogyszerkutato Intezet|Process for producing new, biologically active lysergamides|

---

CH619468A5|1976-01-12|1980-09-30|Sandoz Ag|

---

US4124712A|1976-09-06|1978-11-07|Sandoz Ltd.|Ergot peptide alkaloid derivatives|CH646166A5|1980-09-30|1984-11-15|Linnea Sa|PARTIAL SYNTHESIS PROCEDURE OF VINCAMINE AND RELATED INDOLIC ALCALOIDS.|

---

FR2499589B1|1981-02-06|1985-11-15|Richter Gedeon Vegyeszet|PROCESS FOR ADJUSTING THE QUANTITY AND THE PROPORTIONS OF ALKALOIDS WHICH FORM DURING FERMENTATION|

---

US4390625A|1981-02-06|1983-06-28|Richter Gedeon Vegyeszeti Gyar Rt|Method for controlling the amount and distribution of alkaloids formed in a fermentation process|

---

CH649300A5|1981-08-07|1985-05-15|Sandoz Ag|ERGOPEPTIN DERIVATIVES, THEIR PRODUCTION AND USE.|

---

HU190141B|1983-08-10|1986-08-28|Richter Gedeon Vegyeszeti Gyar Rt,Hu|New process for production of clavin-type rye-smut alcaloids|

---

US5891885A|1996-10-09|1999-04-06|Algos Pharmaceutical Corporation|Method for treating migraine|

---

EP2515654A4|2009-12-23|2013-04-24|Map Pharmaceuticals Inc|Novel ergoline analogs|

---

US8604035B2|2011-06-23|2013-12-10|Map Pharmaceuticals, Inc.|Fluoroergoline analogs|

---

AU2012355982A1|2011-12-19|2014-07-10|Map Pharmaceuticals, Inc.|Novel iso-ergoline derivatives|

---

EP2793583A4|2011-12-21|2015-08-12|Map Pharmaceuticals Inc|Novel neuromodulatory compounds|

---

US9012640B2|2012-06-22|2015-04-21|Map Pharmaceuticals, Inc.|Cabergoline derivatives|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

GB16096/77A|GB1584464A|1977-04-19|1977-04-19|Ergot alkaloids|

---